---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-126240"
form_type: "8-K"
ticker: "RANI"
cik: "0001856725"
company_name: "Rani Therapeutics Holdings, Inc."
filed_at: "2026-03-26T23:59:59+00:00"
generated_at: "2026-05-15T08:53:24.761031+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Rani Therapeutics reports Q4 net loss of $9.1M; announces up to $1.085B Chugai collaboration and $60.3M placement

## Summary
- Collaboration with Chugai for up to $1.085B to develop oral therapy using RaniPill; Chugai may expand to 5 additional targets.
- Raised $60.3M via oversubscribed private placement led by Samsara BioCapital, including $6.0M debt conversion.
- Initiated Phase 1 study of RT-114 (oral GLP-1/GLP-2 dual agonist) via RaniPill for obesity in December 2025.
- Cash and equivalents $49.7M as of Dec 31, 2025; expected to fund operations into Q4 2027, including Chugai milestone.
- Net loss for FY2025 was $41.0M, narrowed from $56.6M in FY2024; R&D expenses decreased 24% to $20.2M.

## SEC filing metadata
- accession: 0001193125-26-126240
- form_type: 8-K
- ticker: RANI
- cik: 0001856725
- company_name: Rani Therapeutics Holdings, Inc.
- filed_at: 2026-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1856725/000119312526126240/0001193125-26-126240-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1856725/000119312526126240/rani-20260326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-126240
- JSON: https://secwatch.observer/filing/0001193125-26-126240.json
- Plain text: https://secwatch.observer/filing/0001193125-26-126240.txt

## Key facts
- Earnings Releases
  Rani Therapeutics Holdings, Inc. reported fourth quarter and year ended December 31, 2025 results: revenue $1.5 million.
  - Period: fourth quarter and year ended December 31, 2025
  - Revenue: $1.5 million
  - Result: reported results
  source text: to the Chugai agreement, to be sufficient to fund its operations into the fourth quarter of 2027. • Contract revenue for the three and twelve months ended December 31, 2025 were $1.5 million and $1.6 million, respectively. Of this, $1.5 million was attributed to a License and Collaboration Agreement and $0.1 million was attributed to evaluation services performed for
  evidence_url: https://www.sec.gov/Archives/edgar/data/1856725/000119312526126240/0001193125-26-126240-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.